Table 4.

Summary of galcanezumab RCTs

Study	Phase	Migraine/N	Study period	Primary outcome
NCT01625988 Dodick et al. (2014) [35]	II	EM N = 218	3 months	placebo: − 3.0 150 mg: − 4.2 (p = 0.003
NCT02959177 Sakai et al. (2020) [36]	II	EM N = 915	6 months	placebo: − 0.59 120 mg: − 3.60 (p < 0.001) 240 mg: − 3.36 (p < 0.001)
NCT02614183 Stauffer et al. (2018) (EVOLVE-1) [37]	III	EM N = 858	6 months	placebo: − 2.8 120 mg: − 4.7 (p < 0.001) 240 mg: − 4.6 (p < 0.001)
NCT02614196 Skljarevski et al. (2018) (EVOLVE-2) [38]	III	EM N = 915	6 months	placebo: − 2.3 120 mg: − 4.3 (p < 0.001) 240 mg: − 4.2 (p < 0.001)
NCT02614261 Detke et al. (2018) (REGAIN) [39]	III	CM N = 1113	3 months	MHD reduction placebo: − 2.7 120 mg: − 4.8 (p < 0.001) 240 mg: − 4.6 (p < 0.001)
NCT03559257 Mulleners et al. (2020) (CONQUER) [41]	III	EM, CM N = 462	3 months	placebo: − 1.0 120 mg: − 4.1 (p < 0.0001)

All studies required ≤ 2 classes of failed preventive treatments except REGAIN (≤ 3 classes) and CONQUER [2–4 classes]. Primary outcome was MMD reduction for all studies except REGAIN

EM episodic migraine, CM chronic migraine, MMD mean monthly migraine day, MHD mean monthly headache day